Business
Abbott Laboratories has agreed to sell its branded generic drug business in developed countries to Mylan Inc. in a deal valued at $5.3 billion.
July 14, 2014
Financier Carl Icahn and his High River affiliate Wednesday said they were again proposing to acquire generic drug maker Mylan Laboratories Inc. for $20 a share, or more than $5 billion.
June 2, 2005
The deal would cut the seller’s debt and let the U.S. firm expand.
May 14, 2007
Antitrust: Mylan Labs, accused of price gouging in federal, state and private suits, agrees to penalty while admitting no wrongdoing.
July 13, 2000
Mylan Laboratories Inc. won U.S. regulatory approval for a generic version of Pfizer Inc.’
Oct. 5, 2005
Mylan Laboratories Inc. said regulators approved its application for a generic version of heartburn drug Prilosec.
June 3, 2003
Carl Icahn dropped his $5.39-billion takeover bid for Mylan Laboratories Inc. and offered to sell his shares after U.S. regulators opened a probe of a Mylan pain patch that was linked to 120 deaths.
July 19, 2005
Mylan Laboratories Inc. said its board adopted a severance plan covering about 2,200 employees to provide “enhanced severance benefits” in the event of involuntary terminations within two years of a change in control.
Dec. 4, 2004
Financier Carl Icahn launched his latest challenge to Mylan Laboratories Inc.’
Feb. 23, 2005
Mylan Laboratories Inc. appeared to back away Wednesday from a contentious $4-billion takeover bid for rival drug maker King Pharmaceuticals Inc.
Jan. 13, 2005